[18F]FDG PET outperforms MRI for detecting early tau-related neurodegeneration.

Structural MRI signature predicts tau staging in Alzheimer's disease

Evidence is provided that multiregion T1‐MRI patterns can inform on tau‐PET burden in AD and may support approximate tau staging when tau‐PET is unavailable, especially in subjects with more advanced tau burden.

Differential associations of tau extent and load with brain metabolic and cognitive dysfunction in Alzheimer's disease

Across regions and networks, SEOT performed similarly or better than tau load in predicting metabolic dysfunction and may improve diagnostic characterisation and prediction of cognitive impairment beyond [18F]FDG-PET.

T1 mapping in Alzheimer’s disease: a quantitative MRI study with amyloid-PET correlation

Quantitative T1 mapping (qT1) is a magnetic resonance imaging (MRI) biomarker of brain microstructural changes; however, its application in Alzheimer disease (AD) remains limited. We compared cortico-limbic qT1 values between patients with AD and healthy controls (HCs) and examined their relationship with amyloid burde...

A review of FDG-PET biomarker analysis methods in Parkinson's disease

Despite well-established clinical diagnostic criteria for Parkinson's disease (PD), challenges remain in early-stage diagnosis, differentiating atypical parkinsonism disorders, and understanding of underlying disease mechanisms. Neuroimaging, particularly positron emission tomography (PET) with [18F]fluorodeoxyglucose...

Metabolic brain network reorganization precedes clinical conversion in Alzheimer’s disease

Brain fluorodeoxyglucose PET anatomical segmentation via AI: extensive validation in the neurodegenerative spectrum.